Vanguard Personalized Indexing Management LLC increased its holdings in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 12.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 133,817 shares of the company’s stock after acquiring an additional 14,381 shares during the quarter. Eli Lilly and Company comprises 1.4% of Vanguard Personalized Indexing Management LLC’s investment portfolio, making the stock its 11th biggest position. Vanguard Personalized Indexing Management LLC’s holdings in Eli Lilly and Company were worth $143,810,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Venture Visionary Partners LLC boosted its position in Eli Lilly and Company by 3.7% during the fourth quarter. Venture Visionary Partners LLC now owns 12,923 shares of the company’s stock worth $13,974,000 after acquiring an additional 462 shares during the last quarter. Panagora Asset Management Inc. boosted its position in Eli Lilly and Company by 82.4% during the fourth quarter. Panagora Asset Management Inc. now owns 337,865 shares of the company’s stock worth $363,097,000 after acquiring an additional 152,682 shares during the last quarter. Perryman Financial Advisory Inc. AD acquired a new position in Eli Lilly and Company during the fourth quarter worth about $2,074,000. Potomac Fund Management Inc. ADV boosted its position in Eli Lilly and Company by 27.9% during the fourth quarter. Potomac Fund Management Inc. ADV now owns 664 shares of the company’s stock worth $713,000 after acquiring an additional 145 shares during the last quarter. Finally, Public Employees Retirement Association of Colorado boosted its holdings in Eli Lilly and Company by 14.6% in the 4th quarter. Public Employees Retirement Association of Colorado now owns 417,597 shares of the company’s stock valued at $448,783,000 after purchasing an additional 53,184 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
LLY has been the topic of several recent analyst reports. Berenberg Bank boosted their target price on shares of Eli Lilly and Company from $950.00 to $1,050.00 and gave the company a “hold” rating in a report on Thursday, February 19th. Weiss Ratings lowered shares of Eli Lilly and Company from a “buy (b)” rating to a “buy (b-)” rating in a report on Tuesday, May 19th. Cantor Fitzgerald boosted their target price on shares of Eli Lilly and Company from $1,205.00 to $1,230.00 and gave the company an “overweight” rating in a report on Friday, May 1st. Wolfe Research reiterated an “outperform” rating and issued a $1,350.00 target price on shares of Eli Lilly and Company in a report on Thursday, May 21st. Finally, Truist Financial reiterated a “buy” rating on shares of Eli Lilly and Company in a report on Monday, February 23rd. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $1,227.74.
Eli Lilly and Company Stock Performance
Shares of LLY stock opened at $1,130.12 on Tuesday. The firm’s 50 day moving average price is $1,002.35 and its 200-day moving average price is $1,016.51. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,182.73. The firm has a market cap of $1.06 trillion, a P/E ratio of 40.15, a P/E/G ratio of 1.24 and a beta of 0.53.
Eli Lilly and Company (NYSE:LLY – Get Free Report) last issued its quarterly earnings data on Thursday, April 30th. The company reported $8.55 EPS for the quarter, topping the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The firm had revenue of $19.80 billion for the quarter, compared to analyst estimates of $17.82 billion. During the same period in the prior year, the business posted $3.34 EPS. The business’s revenue for the quarter was up 55.5% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, equities research analysts predict that Eli Lilly and Company will post 35.8 EPS for the current year.
Eli Lilly and Company Announces Dividend
The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th were paid a $1.73 dividend. The ex-dividend date of this dividend was Friday, May 15th. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 24.58%.
Key Stories Impacting Eli Lilly and Company
Here are the key news stories impacting Eli Lilly and Company this week:
- Positive Sentiment: Insider Monkey highlighted Eli Lilly as one of billionaire Ken Fisher’s top high-growth stock picks, a vote of confidence that may reinforce the market’s view that LLY remains a high-quality growth name. Billionaire Ken Fisher’s Top 5 High-Growth Stock Picks
- Positive Sentiment: Shares could benefit from a PRNewswire update showing Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death in a Phase 3 CLL/SLL trial, suggesting Lilly’s pipeline has catalysts beyond obesity drugs. Lilly’s Jaypirca (pirtobrutinib) significantly reduced the risk…
- Positive Sentiment: A Yahoo Finance article noted that Lilly’s newer JAK2 inhibitor data supports the idea that the company has broader growth drivers and possible upside beyond its obesity franchise. Eli Lilly JAK2 Data Highlights Pipeline Beyond Obesity And Valuation Upside
- Neutral Sentiment: Multiple articles repeated the same bullish thesis that investors still like Eli Lilly for its strong growth, but some are questioning whether the stock’s valuation leaves less room for near-term upside. Should You Buy Eli Lilly Stock Now or Wait for a Dip?
- Negative Sentiment: That same valuation concern could weigh on the stock, since analysts and commentators continue to describe LLY as expensive even after its strong operating performance. Should You Buy Eli Lilly Stock Now or Wait for a Dip?
Eli Lilly and Company Profile
Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.
Featured Articles
- Five stocks we like better than Eli Lilly and Company
- These 5 Companies Just Made a Massive Bet on Themselves
- 5 Stocks Built to Thrive in a Higher-for-Longer Economy
- RH’s Strong Q1 Still Leaves Investors With One Big Question
- Iran Ceasefire or Not, These 3 Companies Could Win
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.
